Impact of a Clinical Pathway for Pelvic Fragility Fractures

计划入组 393 人 · 首次发布于 2023 年 9 月 26 日

Assessment of Treatment Variability for Pelvic Ring Fragility Fractures

计划入组 120 人 · 首次发布于 2026 年 1 月 20 日

Fragility Fractures of the Pelvis (FFP)

计划入组 420 人 · 首次发布于 2019 年 12 月 2 日

Carbazochrome sulfonic acid

C₁₀H₁₂N₄O₅S

Oxerutins

Denosumab(Prolia, Xgeva, Wyost, Jubbonti, Stoboclo, Obodence, Osenvelt, Xbryk, Jubereq, Osvyrti, Evfraxy, Vevzuo, Junod, Conexxence, Yaxwer, Denbrayce, Izamby, Rolcya, Enwylma, Bilprevda, Bomyntra, Zvogra, Degevma, Ponlimsi, Denosumab Intas, Bildyos, Osqay)

Rx

Ucsf Radiopharmaceutical Facility

United States

Celtic Biotech Ltd.

Ireland

Elvir SAS

France

SI-BONE's iFuse TORQ TNT Implant System Receives FDA Clearance for Pelvic Fragility Fractures

Glycocalyx-Edited Stem Cell Infusion Cuts Fragility Fractures by 94% in First-in-Human Osteoporosis Trial

Zoledronic Acid Reduces Fracture Rates in Pediatric Skeletal Fragility